Understanding the mechanism responsible for the outstanding affinity between the novel severe acute respiratory syndrome coronavirus 2 spike (SARS‐CoV‐2 S) and human angiotensin‐converting enzyme 2 (ACE2) is an “urgent challenge” for developing blockers, vaccines, and therapeutic antibodies against the coronavirus disease (COVID‐19) pandemic. This evidence concerns the gene ACE2 and COVID-19.